Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.
Your search for non small cell lung cancer returned 4 results
Gavreto is an oral tyrosine kinase inhibitor.
Pemrydi RTU is expected to be available in the first quarter of 2024.
A regulatory decision is expected on November 27, 2023.